NFE2L2 and cardiomyopathy: However, this notion is challenged by the emerging evidence which revealed a mediator role of Nrf2 in the progression of cardiomyopathies associated with various pathological settings including proteotoxicity associated with aging, myocardial ischemia-reperfusion injury, pressure overload, and type 1 diabetes (Zang et al., 2020a,b).